CSL Limited CSLLY
34.67 USD +0.06 (+0.17%)
At closeNov 12, 2026, 4:00 PM EST
34.65 Day range 35.25
16.01 52-week range 36.88
- YTD
- +20.38%
- 1 year
- +18.45%
News
globenewswire.com BROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDAR Broad Arrow closes a spectacular 2026 auction calendar with second Zürich Auction at the historic Dolder Grand Hotel on 7 November | Highlights include a rare Bianco Fuji Ferrari LaFerrari that sold…
seekingalpha.com CSL Limited (CSLLY) Shareholder/Analyst Call Transcript CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
prnewswire.com CSL appoints Deborah Waterhouse as CEO & Managing Director MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer…
reuters.com Australia's CSL appoints Deborah Waterhouse as CEO Oct 21 (Reuters) - Australia's CSL (CSL.
zacks.com HRMY vs. CSLLY: Which Stock Is the Better Value Option? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two…
prnewswire.com CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras /PRNewswire/ -- CSL y Alentis Therapeutics han anunciado hoy la firma de un acuerdo de colaboración global exclusiva para desarrollar y promocionar
proactiveinvestors.com CSL strikes US$1.6 billion licensing deal for rare disease drug CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting…
reuters.com CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal…
prnewswire.com CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/…
reuters.com Australia's CSL taps Amazon's cloud unit to boost research pipeline Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline.
prnewswire.com Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.
zacks.com Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
cnbc.com Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals…
seekingalpha.com CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
reuters.com Australia's CSL reports 2% fall in annual profit Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
zacks.com CSL Q2 Earnings Beat Estimates on Record Sales, Outlook Raised Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.
reuters.com CSL to start clinical trials for new immunoglobulin manufacturing process Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the…
prnewswire.com CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE) CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific…
benzinga.com EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims (UPDATED) EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany and France.
prnewswire.com CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026…
globenewswire.com CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations SYDNEY, June 12, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, and Adbri announce the delivery of MV Yampu, the world's first…
benzinga.com Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday - benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
benzinga.com Stocks That Hit 52-Week Highs On Thursday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Wednesday - benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Thursday - benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
benzinga.com Stocks That Hit 52-Week Highs On Monday - benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday